464 Shares in Eli Lilly and Company $LLY Acquired by Polaris Financial Partners

Polaris Financial Partners purchased a new position in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 464 shares of the company’s stock, valued at approximately $551,000.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Bank of America Corp DE bought a new stake in Eli Lilly and Company during the second quarter valued at about $13,522,666,000. Jupiter Topco LLC bought a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $4,667,180,000. Fifth Third Bancorp lifted its holdings in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock worth $1,805,959,000 after purchasing an additional 1,497,423 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in Eli Lilly and Company by 353.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,550,234 shares of the company’s stock worth $1,425,859,000 after purchasing an additional 1,208,510 shares during the period. Finally, Corient Private Wealth LP bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $764,116,000. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock worth $15,958,170 in the last quarter. 0.14% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Jefferies Financial Group boosted their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research note on Tuesday, June 9th. Morgan Stanley restated an “overweight” rating and set a $1,419.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. HSBC raised their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. Finally, UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,311.96.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA expanded Jaypirca (pirtobrutinib) for certain adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without a known 17p deletion. The first-line approval broadens the drug’s addressable market and could support future oncology revenue. Jaypirca FDA expanded indication
• Positive Sentiment: New data strengthened Lilly’s obesity and diabetes pipeline. The oral GLP-1 Foundayo (orforglipron) demonstrated cardiovascular safety, sustained A1C and weight benefits, and favorable predicted reductions in long-term diabetes and cardiovascular risk. Foundayo risk-reduction data
• Positive Sentiment: Mid-stage results for EloraTZP, a combination of eloralintide and tirzepatide, showed weight loss of as much as 23.3% after 48 weeks in patients with type 2 diabetes. The results support Lilly’s strategy of adding amylin-based therapies to Zepbound and Mounjaro, potentially extending its obesity-market lead. EloraTZP obesity data
• Neutral Sentiment: Lilly received permits for a planned $3 billion pharmaceutical plant in Katwijk, Netherlands. The facility may expand long-term manufacturing capacity, but construction spending and the extended timeline limit any immediate earnings effect. Katwijk plant permits
• Negative Sentiment: Lilly ended its cancer-development partnership with Foghorn Therapeutics after disappointing early results. The move appears financially limited for Lilly but highlights pipeline execution risk and resulted in major layoffs at Foghorn. Foghorn partnership termination
• Negative Sentiment: Investors remain concerned that lower Zepbound and Mounjaro pricing could pressure revenue growth. LLY also trades at a demanding valuation, while a late-session decline in healthcare stocks added broader market pressure.

Eli Lilly and Company Trading Down 0.5%

Eli Lilly and Company stock traded down $5.65 during midday trading on Friday, reaching $1,144.20. The stock had a trading volume of 2,051,176 shares, compared to its average volume of 2,987,583. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm has a market cap of $1.08 trillion, a price-to-earnings ratio of 38.40, a price-to-earnings-growth ratio of 1.42 and a beta of 0.46. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65. The company has a fifty day moving average of $1,177.37 and a 200 day moving average of $1,088.38.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion during the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts anticipate that Eli Lilly and Company will post 36.66 earnings per share for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.